Springe direkt zu Inhalt

Dr. Ronan Murphy

Murphy, Ronan_Bio photo_Apr2025

AG Rolff - Evolutionsbiologie

Institut für Biologie

Freie Universität Berlin

Postdoc

Adresse
Königin-Luise-Str. 1-3
Raum 105
14195 Berlin
2025- Present  Postdoctoral Research Fellow (DFG). Freie Universität Berlin, Germany
 2023 - 2024  Postdoctoral Researcher. Freie Universität Berlin, Germany
 2017 - 2022  PhD Research. Imperial College London, United Kingdom
 2015 - 2022  Research Technician. Imperial College London, United Kingdom
 2013 - 2015  Research Assistant. Queen Mary University of London, United Kingdom
 2009 - 2013  Research Assistant. Environmental Research Institute, University College Cork, Ireland
 2008  MSc in Microbiology (Research). University College Cork, Ireland
 2005  BSc in Microbiology. University College Cork, Ireland

I am a microbiologist with Bachelor and Master’s degrees from University College Cork, Ireland, and I earned a PhD from Imperial College London. My research includes antimicrobial resistance evolution in bacteria, antimicrobial combinations and antimicrobial peptides. I am interested in how and when bacteria evolve antimicrobial resistance and novel treatments and strategies which treat bacterial infections while limiting future resistance generation, to help alleviate the antimicrobial resistance crisis.

Peer-reviewed Publications

Murphy, R.A., Pizzato, J., Cuthbertson, L., Sabnis, Edwards, A.M., Nolan, L.M., Vorup-Jensen, T., Larrouy-Maumus, G.J. & Davies, J.C., 2024. Antimicrobial peptide glatiramer acetate targets Pseudomonas aeruginosa lipopolysaccharides to breach membranes without altering lipopolysaccharide modification. npj Antimicrobials and Resistance, 2(1), p.4. doi: https://doi.org/10.1038/s44259-024-00022-x.

Robinson, L., Collins, A.C., Murphy, R.A., Davies, J.C. & Allsopp, L.P., 2023. Diversity and prevalence of type VI secretion system effectors in clinical Pseudomonas aeruginosa isolates. Front Microbiol, p.4966. doi: https://doi.org/10.3389/fmicb.2022.1042505.

Murphy, R.A., Coates, M., Thrane, S., Sabnis, A., Harrison, J., Schelenz, S., Edwards, A.M., Vorup-Jensen, T. & Davies, J.C., 2022. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin Against Cystic Fibrosis Pseudomonas aeruginosa. Microbiol Spectr Vol. 10, No. 4. doi: https://doi.org/10.1128/spectrum.00813-22.

Sabnis, A., Hagart, K.L., Klöckner, A., Becce, M., Evans, L.E., Furniss, R.C.D., Mavridou,D.A., Murphy, R., Stevens, M.M., Davies, J.C., Larrouy-Maumus, G.J., Clarke, T.B. & Edwards, A.M., 2021. Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane. elife, 10, p.e65836. doi: https://doi.org/10.7554/eLife.65836.

Davies, J.C., Alton, E., Simbo, A., Murphy, R., Seth, I., Williams, K., Somerville, M., Jolly, L., Morant, S. & Guest, C., 2019. Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at? Eur Respir J, 54(5). doi: https://doi.org/10.1183/13993003.00970-2019.

Spyridou, C., Ragab, H., Murphy, R.A., Riddell, A., Wilks, M., Millar, M.R. and Prendergast, A.J., 2019. Two cases of BCG osteomyelitis diagnosed through polymerase chain reaction/electrospray ionization-mass spectrometry technology. Clinical Infectious Diseases, 68(2), pp.350-350. doi: https://doi.org/10.1093/cid/ciy105.

Turnbull, A.R., Murphy, R., Behrends, V., Lund-Palau, H., Simbo, A., Mariveles, M., Alton, E.W., Bush, A., Shoemark, A. and Davies, J.C., 2018. Impact of T2R38 receptor polymorphisms on Pseudomonas aeruginosa infection in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine, 197(12), pp.1635-1638. doi: https://doi.org/10.1164/rccm.201711-2365LE.

Christiansen, S.H., Murphy, R.A., Juul-Madsen, K., Fredborg, M., Hvam, M.L., Axelgaard, E., Skovdal, S.M., Meyer, R.L., Sørensen, U.B.S., Möller, A. and Nyengaard, J.R., Nørskov-Lauritsen, N., Wang, M., Gadjeva, M., Howard, K.A., Davies, J.C., Petersen, E., & VorupJensen, T., 2017. The immunomodulatory drug glatiramer acetate is also an effective antimicrobial agent that kills gram-negative bacteria. Sci Rep, 7(1), pp.1-16. doi: https://doi.org/10.1038/s41598-017-15969-3.

Smith, W.D., Bardin, E., Cameron, L., Edmondson, C.L., Farrant, K.V., Martin, I., Murphy, R.A., Soren, O., Turnbull, A.R., Wierre-Gore, N. and Alton, E.W., 2017. Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis. FEMS microbiology letters, 364(14), p.fnx121. doi: https://doi.org/10.1093/femsle/fnx121.

Zhou, Z., McCann, A., Litrup, E., Murphy, R., Cormican, M., Fanning, S., Brown, D., Guttman, D.S., Brisse, S. & Achtman, M., 2013. Neutral genomic microevolution of a recently emerged pathogen, Salmonella enterica serovar Agona. PLoS Genet, 9(4), p.e1003471. doi: https://doi.org/10.1371/journal.pgen.1003471.

Achtman, M., Hale, J., Murphy, R.A., Boyd, E.F. and Porwollik, S., 2013. Population structures in the SARA and SARB reference collections of Salmonella enterica according to MLST, MLEE and microarray hybridization. Infection, Genetics and Evolution, 16, pp.314-325. doi: https://doi.org/10.1016/j.meegid.2013.03.003.

O’Farrell, B., Haase, J.K., Velayudhan, V., Murphy, R.A. and Achtman, M., 2012. Transforming microbial genotyping: a robotic pipeline for genotyping bacterial strains. PLoS One, 7(10), p.e48022. doi: https://doi.org/10.1371/journal.pone.0048022.

Haase, J.K., Murphy, R.A., Choudhury, K.R. and Achtman, M., 2011. Revival of Seeliger's historical ‘Special Listeria Culture Collection’. Environmental microbiology, 13(12), pp.3163-3171. doi: https://doi.org/10.1111/j.1462-2920.2011.02610.x

Murphy, R.A. & Boyd, E.F., 2008. Three pathogenicity islands of Vibrio cholerae can excise from the chromosome and form circular intermediates. J Bacteriol, 190(2), pp.636-647. doi: https://doi.org/10.1128/JB.00562-07.